ArticleJAMA2022
Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection.
Article in JAMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: mathematical modelling analyses.Sexually transmitted infections · 2025Pooled it
- Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects.Journal of clinical pharmacology · 2026Trial
- Projected public health benefits of a hypothetical HSV-1 vaccine in the United States: A mathematical modeling analysis.Science advances · 2026Article
- Genital Herpes Simplex Virus (HSV) Infection During Pregnancy - Recommendations of the Working Group on Obstetrics and Prenatal Medicine (AGG - Section on Maternal Disorders).Geburtshilfe und Frauenheilkunde · 2026Article
- Clinical trial simulation of antiviral drugs.Journal of virology · 2026Review
- Maternal-Fetal Implications of Herpes Virus Infection: An Updated Review.Diagnostics (Basel, Switzerland) · 2026Review
- Developments in genital herpes: progress in prevention and treatment.Current opinion in infectious diseases · 2026Review
- Sexually Transmitted Infections in adolescents and young adults: a growing public health challenge.Le infezioni in medicina · 2026Review
- What you see is not always what you get: the influence of epidemiology on ordering practices for herpes simplex virus and varicella zoster virus.ASM case reports · 2026Article
- Epidemiological Characteristics of HSV-1 and HSV-2 in 177,599 Patients Based on PCR Testing in South Korea (2018-2022).Pathogens (Basel, Switzerland) · 2025Article
- Rapid detection of herpes simplex virus types 1 and 2 using a G-quadruplex aptamer-based biosensor.Virology journal · 2025Article
- Age-Dependent Assortativeness in Herpes Simplex Virus Type 1 Oral Transmission in the United States: A Mathematical Modeling Analysis.The Journal of infectious diseases · 2025Article
- Herpesvirus-associated diseases: biomarkers and advancements in clinical research.Virology journal · 2025Review
- Neonatal Meningitis Due to Herpes Simplex Virus Type 1 and Enterovirus Coinfection: Case Report and Review of the Literature.Viruses · 2025Review
- Intracellular and extracellular dynamics of herpes simplex virus 1 DNA and infectious particles in epithelial and neuronal cells.bioRxiv : the preprint server for biology · 2025Article
- Regulation of inflammatory cytokines and activation of PI3K/Akt pathway by Yiqi Jiedu Formula in recurrent Herpes Simplex Keratitis: Experimental and network pharmacology evidence.Virus research · 2025Article
- IP6K2 mutations as a novel mechanism of resistance to oncolytic virus therapy.Journal of translational medicine · 2025Article
- Article
- Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium at pharyngeal and anorectal sites in patients presenting to an STI outpatient ward.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Observational
- Debulking influenza and herpes simplex virus strains by a wide-spectrum anti-viral protein formulated in clinical grade chewing gum.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
Importance: Herpes simplex virus type 1 (HSV-1) is the leading cause of first-episode genital herpes in many countries. Objective: To inform counseling messages regarding genital HSV-1 transmission, oral and genital viral shedding patterns among persons with first-episode genital HSV-1 infection were assessed. The trajectory of the development of HSV-specific antibody and T-cell responses was also characterized. Design, Setting, and Participants: Prospective cohort followed up for up to 2 years, with 82 participants followed up between 2013 and 2018. Participants were recruited from sexual health and primary care clinics in Seattle, Washington. Persons with laboratory-documented first-episode genital HSV-1 infection, without HIV infection or current pregnancy, were referred for enrollment. Exposures: First-episode genital HSV-1 infection. Main Outcomes and Measures: Genital and oral HSV-1 shedding and lesion rates at 2 months, 11 months, and up to 2 years after initial genital HSV-1 infection. Participants self-collected oral and genital swabs for HSV polymerase chain reaction testing for 30 days at 2 and 11 months and up to 2 years after diagnosis of genital HSV-1. Blood samples were collected at serial time points to assess immune responses to HSV-1. Primary HSV-1 infection was defined as absent HSV antibody at baseline or evolving antibody profile using the University of Washington HSV Western Blot. HSV-specific T-cell responses were detected using interferon γ enzyme-linked immunospot. Results: Among the 82 participants, the median (range) age was 26 (16-64) years, 54 (65.9%) were women, and 42 (51.2%) had primary HSV-1 infection. At 2 months, HSV-1 was detected from the genital tract in 53 participants (64.6%) and in the mouth in 24 participants (29.3%). Genital HSV-1 shedding was detected on 275 of 2264 days (12.1%) at 2 months and declined significantly to 122 of 1719 days (7.1%) at 11 months (model-predicted rate, 6.2% [95% CI, 4.3%-8.9%] at 2 months vs 3.2% [95% CI, 1.8%-5.7%] at 11 months; relative risk, 0.52 [95% CI, 0.29-0.93]). Genital lesions were rare, reported on 65 of 2497 days (2.6%) at 2 months and 72 of 1872 days (3.8%) at 11 months. Oral HSV-1 shedding was detected on 88 of 2247 days (3.9%) at 2 months. Persons with primary HSV-1 infection had a higher risk of genital shedding compared with those with nonprimary infection (model-predicted rate, 7.9% [95% CI, 5.4%-11.7%] vs 2.9% [95% CI, 1.7%-5.0%]; relative risk, 2.75 [95% CI, 1.40-5.44]). Polyfunctional HSV-specific CD4+ and CD8+ T-cell responses were maintained during the follow-up period. Conclusions and Relevance: Genital HSV-1 shedding was frequent after first-episode genital HSV-1, particularly among those with primary infection, and declined rapidly during the first year after infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.